Fundraising FoxNeurana Pharmaceuticals
San Diego, US · Founded 2013 · Delaware corporation · 6 known investors
Find your way into Neurana Pharmaceuticals
Sign up to see every warm intro you have to Neurana Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurana Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developing a novel treatment for acute muscle spasms.
Founders & leadership
Board
Investors · 6
How we know: Sofinnova Ventures's portfolio page · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$45.7M disclosed across 2 of 3 rounds · 2013–2020
▶$41.9MraisedFeb 2020 · 14 investors · BiotechnologyRule 506(b)
- Joshua RichardsonDirector
- David KabakoffDirector
- Craig ThompsonDirector, Executive Officer
- Brian DorseyDirector
- David F. HaleDirector
- Randall Kaye, M.D.Executive Officer
- Kathleen D. ScottExecutive Officer
- Alex ZissonDirector
- Offering amount
- $64.9M
- Amount sold
- $41.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedMay 2018 · 8 investors · BiotechnologyRule 506(b)
- Kathleen D. ScottExecutive Officer
- Judy CaronExecutive Officer
- David F. HaleDirector, Executive Officer
- Brian DorseyDirector
- Daniel BeckerDirector
- Alex ZissonDirector
- David KabakoffDirector
- Joshua RichardsonDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Neurana Pharmaceuticals do?
- Developing a novel treatment for acute muscle spasms.
- Who are Neurana Pharmaceuticals's investors?
- Neurana Pharmaceuticals's investors include Sofinnova Ventures, H.I.G. BioHealth Partners, H.I.G. HealthBridge Partners, HealthQuest Capital, Longitude Capital, New Leaf Venture Partners.
- How much funding has Neurana Pharmaceuticals raised?
- Neurana Pharmaceuticals has disclosed $45.7M raised across 2 of its 3 known rounds.
- Where is Neurana Pharmaceuticals headquartered?
- Neurana Pharmaceuticals is headquartered in San Diego, US.